Recerca > Càncer

Grup de recerca de biomarcadors en càncer (GReBiC)

Nombre de publicacions
495
Cercador de publicacions

  • Roman-Canal, B; Moiola, CP; Gatius, S; Bonnin, S; Ruiz-Miro, M; Gonzalez, E; Gonzalez-Tallada, X; Llordella, I; Hernandez, I; Porcel, JM; Gil-Moreno, A; Falcon-Perez, JM; Ponomarenko, J; Matias-Guiu, X; Colas, E

    EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer

    Cancers 11 -. .

    [doi:10.3390/cancers11060839]

  • Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Muñoz-Unceta N; Jimeno, R; Lopez, C

    Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 83 1175-1181. .

    [doi:10.1007/s00280-019-03820-7]

  • Aapro, M; Ruiz-Borrego, M; Hegg, R; Kukielka-Budny, B; Morales, S; Cinieri, S; Freitas, R; Garcia-Estevez, L; Szombara, E; Borges, GS; Passalacqua, R; Hervieu, H; Groc, M; Villanova, G

    Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial)

    BREAST 45 7-14. .

    [doi:10.1016/j.breast.2019.01.009]

  • Mercer, RM; Corcoran, JP; Porcel, JM; Rahman, NM; Psallidas, I

    Interpreting pleural fluid results

    CLINICAL MEDICINE 19 213-217. .

    [doi:10.7861/clinmedicine.19-3-213]

  • Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E

    Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

    ANNALS OF ONCOLOGY 30 796-803. .

    [doi:10.1093/annonc/mdz082]

  • Pascual, T; Martin, M; Fernandez-Martinez, A; Pare, L; Alba, E; Rodriguez-Lescure, A; Perrone, G; Cortes, J; Morales, S; Lluch, A; Urruticoechea, A; Gonzalez-Farre, B; Galvan, P; Jares, P; Rodriguez, A; Chic, N; Righi, D; Cejalvo, JM; Tonini, G; Adamo, B; Vidal, M; Villagrasa, P; Muñoz M; Prat, A

    A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in oncology 9 303-303. .

    [doi:10.3389/fonc.2019.00303]

  • MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VEAS RODRIGUEZ, JOEL; SANTACANA ESPASA, MARIA; MELE OLIVE, JORDI; CANOSA MORALES, CARLOS; IGLESIAS MARTINEZ, EDELMIRO

    Vitamin D as A Prognostic Factor in Triple Negative Breast Cancer

    Annals of Cancer Therapy and Pharmacology 2 1-8. .

  • Blancas, I; Aguirre, E; Morales, S; Gonzalvez, ML; Servitja, S; Diaz, N; del Barco, S; Barnadas, A; Margeli, M; García Carbonero I; Llombart, A

    Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens

    CLINICAL & TRANSLATIONAL ONCOLOGY 21 459-466. .

    [doi:10.1007/s12094-018-1946-9]

  • MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VELASCO SANCHEZ, ANA; MARTINEZ ORTIN, DAVID; SALLA FORTUNY, JOEL; TEJERO NARBONA, RUBEN; SERRATE LOPEZ, ANNA ALBA; VILARDELL VILLELLAS, FELIPE; SALUD SALVIA, ANTONIA

    Clinical and Biological Factors Associated with ISH Amplification in HER2 2+ by IHC in Breast Cancer Patients

    Biomedical Journal of Scientific & Technical Research -. .

    [doi:10.26717/BJSTR.2019.16.002860]

  • Porcel, JM; Cuadrat, I; Garcia-Cerecedo, T; Pardina, M; Bielsa, S

    Pleural Effusions in Diffuse Large B-Cell Lymphoma: Clinical and Prognostic Significance

    Lung 197 47-51. .

    [doi:10.1007/s00408-018-0182-y]

  • Gavila, J; Oliveira, M; Pascual, T; Perez-Garcia, J; Gonzàlez X; Canes, J; Pare, L; Calvo, I; Ciruelos, E; Muñoz M; Virizuela, JA; Ruiz, I; Andres, R; Perello, A; Martinez, J; Morales, S; Marin-Aguilera, M; Martinez, D; Quero, JC; Llombart-Cussac, A; Prat, A

    Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    BMC MEDICINE 17 8-8. .

    [doi:10.1186/s12916-018-1233-1]

  • Bibby, AC; Dorn, P; Psallidas, I; Porcel, JM; Janssen, J; Froudarakis, M; Subotic, D; Astoul, P; Licht, P; Schmid, R; Scherpereel, A; Rahman, NM; Maskell, NA; Cardillo, G

    ERS/EACTS statement on the management of malignant pleural effusions

    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY 55 116-132. .

    [doi:10.1093/ejcts/ezy258]